서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Title

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 81 to 100 of 4,466

Issue DateTitle / Author(s) / CitationFileAltmetrics
1998
A novel approach to glioma gene therapy: Down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes

Ke, L.D.; Fueyo, J.; Chen, X.; Steck, P.A.; Shi, Y.-X.; Im, S.-A.; Yung, W.K.A.

International Journal of Oncology, Vol.12 No.6, pp.1391-1396

DOI
2019-07
A novel de novo mutation in MYH7 gene in a patient with early onset muscular weakness and severe kyphoscoliosis: A case report
DOI
1998-01
A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-β type II receptor
DOI
2003-10
A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells
DOI
2022-04
A novel Vascular Leak Index identifies sepsis patients with a higher risk for in-hospital death and fluid accumulation
DOI
2020-04
A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy
view filelink
2021-01
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients withEGFRmutation-positive locally advanced/metastatic non-small-cell lung cancer
DOI
2017-08
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
DOI
2022-07
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer
2024-04
A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer
DOI
2017-09
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
view fileDOI
2001-04
A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies
DOI
2014-07
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HIVI30181A, in Patients with Advanced Solid Cancer
DOI
2016-07
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors
DOI
2010-09
A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma
DOI
2019-11
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
DOI
2015-06
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
DOI
2021-01
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
DOI
2008-05
A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker
DOI
2014-02
A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
DOI
1 2 3 4 5 6224